Team
Jonas Wang, Ph.D.
Jonas Wang, Ph.D.
StemCyte International, Ltd.
－ Chairman
- Distinguished Alumnus of the University of Iowa
- Vice President of Research, Consumer Products Division, Johnson & Johnson
- Director of Drug Delivery Technology Resources Center, Johnson & Johnson
- Partner at Sycamore Management Corporation
Dr. Wang joined StemCyte in 2009 and has held various positions including Vice President of Consumer Products Research at Johnson & Johnson, Director of Drug Delivery Technology Resources Center at Johnson & Johnson, and Deputy Director of Basic Drug Department at BMS Drug R&D Center. With over 30 years of experience in pharmaceutical research management and business development, Dr. Wang is highly knowledgeable in the field. Dr. Wang was also a partner at Sycamore Management Corporation, specializing in investments in life sciences and biotechnology.
He has been recognized as an outstanding alumni of both the Republic of China Military Academy and the University of Iowa. During his tenure at Johnson & Johnson, Dr. Wang developed more than 10 core technologies and filed over 30 patents. His expertise and contributions have made a significant impact in the pharmaceutical industry.
Tong-Young Lee, Ph.D.
Tong-Young Lee, Ph.D.
StemCyte Inc.
－ CEO
StemCyte Taiwan
－ Chairman
StemCyte Taiwan
－ CEO
- Ph.D. in Pathology, National Taiwan University College of Medicine
- Lecturer at Harvard University Medical School
- Independent Director of Senhwa Biotech, a publicly traded company
- Project Review Committee Member for the Ministry of Science and Technology and Institute for Biotechnology and Medicine Industry
Dr. Lee joined the renowned cancer angiogenesis research laboratory of Dr. Judah Folkman at Harvard Medical School, which is considered one of the top cancer research institutions in the world, in 2004. During his time there, he was involved in the research and development of cancer treatments, including Avastin, Lucentis, and Eylea, which collectively generate annual sales exceeding $15 billion. Additionally, Dr. Lee is credited as the inventor of Fc-endostatin, a next-generation long-acting angiogenesis inhibitor.
In 2010, Dr. Lee returned to Taiwan and joined the Chintek Group, where he participated in the development of several antibody-based drugs. Among them, the monoclonal antibody drug FB825 recently garnered a historic licensing deal of $530 million with a major international pharmaceutical company. Over the past 15 years, Dr. Lee has been involved in the development of products and corporate governance in four startup companies, encompassing activities such as spin-offs, establishment, initial public offerings (IPOs), stock exchange listings, and mergers and acquisitions.
Joseph Rosenthal, M.D.
Joseph Rosenthal, M.D.
StemCyte Inc.
－ Chief Medical Officer
- M.D. , Harvard University of Public Health
- Director of Pediatric Hematology/Oncology at City of Hope Medical Center, United States
Professor Rosenthal has been with City of Hope for over twenty years since joining in 1996. He has dedicated himself to research in the field of pediatric hematologic malignancies and bone marrow transplantation, and is an expert in the field of umbilical cord blood transplantation and clinical applications. His motto is “fighting for every child, making diseases as if they never occurred,” aiming to help patients fully recover and regain a healthy life.
Founded in 1913, City of Hope is a comprehensive cancer center designated by the National Cancer Institute (NCI) in the United States. It has been recognized as one of the “Best Cancer Hospitals in America” by US News & World Report for over a decade. City of Hope has successfully performed over 15,000 bone marrow and stem cell transplants, with an unparalleled survival rate for thirteen consecutive years.